Medical

Altimmune has announced that a study of its AdCOVID intranasal vaccine candidate induced a strong immune response in a mouse model. The results support advancing AdCOVID into a Phase 1 development, the company said, and it plans to begin manufacturing the vaccine for a trial in the fourth quarter of this year. The company recently said that it has partnered with … [Read more...] about Preclinical studies of Altimmune’s AdCOVID intranasal vaccine candidate demonstrate strong immune response in mice

Vienna-based biotech incubator CEBINA (Central European Biotech Incubator and Accelerator) said that in vitro testing has shown that azelastine has anti-SARS-CoV-2 activity, and the company is discussing possible development and production of an azelastine nasal spray for the treatment of COVID-19 with Sigmapharm. CEBINA added that it has also filed a patent … [Read more...] about CEBINA says azelastine nasal spray has potential for COVID-19

Dutch inhaled drug developer PureIMS said that it has initiated a Phase 1 clinical trial of its Amikacin Cyclops DPI, which it is developing for the treatment of drug susceptible tuberculosis. The single ascending dose study is expected to enroll eight tuberculosis patients, with results anticipated later this year. The dry powder amikacin formulation is … [Read more...] about PureIMS initiates Phase 1 trial of amikacin DPI for tuberculosis

Orexo has announced that a Phase 1 bioavailability study of three formulations of its OX125 intranasal nalmefene compared to intramuscular nalmefene injection showed that all three were well tolerated and well absorbed. Orexo is developing both the nasal formulation of nalmefene and a nasal formulation of naloxone for the treatment of opioid overdose. Orexo VP … [Read more...] about Positive Phase 1 results for Orexo’s nasal nalmefene

TFF Pharmaceuticals has announced topline safety results from a Phase 1 trial of its inhaled dry powder voriconazole, which is in development for the treatment of invasive pulmonary aspergillosis. The study demonstrated that doses as high as 80 mg were well tolerated with no occurrence of side effects such as kidney damage or vision changes that limit doses of oral … [Read more...] about TFF reports positive safety data from Phase 1 trial of inhaled voriconazole, initiation of inhaled tacrolimus study

AstraZeneca said that complete results from the Phase 3 ETHOS trial of its Breztri Aerosphere (PT010) budesonide/glycopyrronium/formoterol fumarate MDI demonstrated that the triple combination reduced moderate or severe COPD exacerbations by 24% compared to glycopyrronium/formoterol fumarate and by 13% compared to budesonide/formoterol fumarate. Patients using … [Read more...] about Breztri Aerosphere triple combination MDI outperforms dual combination therapies in Phase 3 trial

Gilead Sciences Chairman and CEO Daniel O'Day has announced that the company has received FDA approval for a Phase 1 trial of inhaled remdesivir and will initiate the study within a week. Trials of the inhaled antiviral formulation in COVID-19 patients are expected to begin in August 2020. O'Day said, "Remdesivir, our investigational antiviral medicine, is … [Read more...] about Gilead announces Phase 1 trial of inhaled remdesivir

Vaccine developer Intravacc has published data from a preclinical study of an intranasal whooping cough vaccine demonstrating strong immune responses in mice. The intranasal vaccine also prevented colonization of the lung, trachea, and nose by B. pertussis, the bacteria that causes whooping cough, while mice vaccinated by subcutaneous injection did experience nasal … [Read more...] about Preclinical study demonstrates potential of IntraVacc intranasal pertussis vaccine

Impel NeuroPharma has announced that the Phase 3 STOP 301 study of INP104 intranasal dihydroergotamine mesylate (DHE) for the treatment of acute migraine met its primary objectives, with 66.3% of patients experiencing pain relief and 38% experiencing freedom from pain two hours post dose. Pain relief began as early as 15 minutes post dose for 16.3% of patients using … [Read more...] about Positive Phase 3 results for Impel’s INP104 intranasal DHE for the treatment of migraine